Chanrx Corp. moved a step closer to the goal line for lead candidate vanoxerine (GBR-12909), reporting Phase IIb data at the American Heart Association (AHA) 2013 Scientific Sessions suggesting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback